Skip to main content

Main menu

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 Articles
  • Authors
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
  • CMA Members
    • Overview for members
    • Earn CPD Credits
    • Print copies of CMAJ
  • Subscribers
    • General information
    • View prices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2022
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN

User menu

Search

  • Advanced search
CMAJ
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN
CMAJ

Advanced Search

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 Articles
  • Authors
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
  • CMA Members
    • Overview for members
    • Earn CPD Credits
    • Print copies of CMAJ
  • Subscribers
    • General information
    • View prices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2022
  • Visit CMAJ on Facebook
  • Follow CMAJ on Twitter
  • Follow CMAJ on Pinterest
  • Follow CMAJ on Youtube
  • Follow CMAJ on Instagram
News

HTLV-1 virus detected in Nunavut

Barbara Sibbald
CMAJ January 17, 2006 174 (2) 150-151; DOI: https://doi.org/10.1503/cmaj.051581
Barbara Sibbald
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Tables
  • Responses
  • Metrics
  • PDF
Loading

Nunavut health officials report at least one death related to human T-cell lymphotropic virus type 1 (HTLV-1) and “fewer than 20” infected persons.

Nunavut's Medical Officer of Health, Dr. Issac Sobol, says residents need to take this very seriously, but adds, “It's not what we consider an outbreak. In fact, it's been here a number of years.” It can take up to 20 years before symptoms appear. There is no effective treatment to reduce the viral load.

In response to the death and reported cases, the Nunavut Department of Health and Social Services began offering testing for HTLV-1 to pregnant women and the population in general in October, “We worried about our capacity to handle demand [from the general population],” says Sobol. As of Dec. 7, only 300 people had been tested.

Figure

Figure. Custom condom wrappers, community events, posters and other strategies help prevent the spread of STDs, including HTLV-1, in Nunavut. Photo by: Pauktuutit

Sobol would not disclose the precise number of people infected or the number of HTLV-1–related deaths. He stated that such caution is common in sparsely populated areas where anonymity is difficult. It is important to “ensure that Nunavummiut feel absolutely confident that no information will ever be revealed that could in any way be traced back to either communities or to individuals.” Even one death in a small community could raise suspicions.

HTLV-1 is rare in Canada (see Box 1), but the number of cases is not known because it's not a reportable disease in most jurisdictions. Canadian Blood Services has been screening donated blood for HTLV-1 since 1990 and reports an average of 10–12 positive tests per 800 000 donations annually (prevalence of 0.0014%). If even 15 people in Nunavut are infected, among a population of 29 000, the prevalence is 0.05%.

Figure
  • Download figure
  • Open in new tab
  • Download powerpoint

Box 1.

HTLV-1 can be transmitted sexually, which is cause for concern. “We know that there are still high levels of unprotected sex occurring because of our static chlamydia rates,” says Dr. Geraldine Osborne, Nunavut's associate chief medical officer of health. Chlamydia rates have remained fairly stable since 1991 at 2500 per 100 000 population, compared to 188 per 100 000 in Canada generally. Gonorrhea rates have declined from 900 per 100 000 in 1991 to 250 today, largely due to “effective treatment and contact tracing,” says Osborne. Rates for other STIs including syphylis and HIV are very low; less than 20 reported cases each.

HTLV-1 will top the agenda at a sexual health symposium at the end of February, says Aideen Reynolds, manager of Sexual Health Policy and Program for Pauktuutit, an Ottawa-based NGO that has offered STI prevention programs for the North since 1999.

Reynolds says the problems are myriad: “How do you mobilize communities to take it on and believe that they are at risk?”

Part of the solution involves proving risk. The Nunavut department of health and the Public Health Agency of Canada (PHAC) are developing a seroprevalence study that includes anonymous testing of all blood samples taken in the territory. Preliminary results are expected by June; statistically significant results will take 2 years.

Dr. Frank Plummer, director general of PHAC's Centre for Infectious Disease Prevention and Control says HTLV-1 is ”not a huge public health threat.” The important thing is to ensure there is antenatal screening in areas where there is an appreciable prevalence, he adds.

PreviousNext
Back to top

In this issue

Canadian Medical Association Journal: 174 (2)
CMAJ
Vol. 174, Issue 2
17 Jan 2006
  • Table of Contents
  • Index by author

Article tools

Respond to this article
Print
Download PDF
Article Alerts
To sign up for email alerts or to access your current email alerts, enter your email address below:
Email Article

Thank you for your interest in spreading the word on CMAJ.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
HTLV-1 virus detected in Nunavut
(Your Name) has sent you a message from CMAJ
(Your Name) thought you would like to see the CMAJ web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
HTLV-1 virus detected in Nunavut
Barbara Sibbald
CMAJ Jan 2006, 174 (2) 150-151; DOI: 10.1503/cmaj.051581

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
‍ Request Permissions
Share
HTLV-1 virus detected in Nunavut
Barbara Sibbald
CMAJ Jan 2006, 174 (2) 150-151; DOI: 10.1503/cmaj.051581
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
  • Figures & Tables
  • Responses
  • Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • Human T-cell lymphotropic virus type 1-associated adult T-cell leukemia/lymphoma in the Inuit people of Nunavut.
  • Google Scholar

More in this TOC Section

  • Is one-way masking enough?
  • XE, XD & XF: what to know about the Omicron hybrid variants
  • 5 infectious disease topics to watch
Show more News

Similar Articles

Collections

  • Topics
    • HIV & AIDS
    • Sexually transmitted infections

 

View Latest Classified Ads

Content

  • Current issue
  • Past issues
  • Collections
  • Sections
  • Blog
  • Podcasts
  • Alerts
  • RSS
  • Early releases

Information for

  • Advertisers
  • Authors
  • Reviewers
  • CMA Members
  • Media
  • Reprint requests
  • Subscribers

About

  • General Information
  • Journal staff
  • Editorial Board
  • Advisory Panels
  • Governance Council
  • Journal Oversight
  • Careers
  • Contact
  • Copyright and Permissions
  • Accessibiity
  • CMA Civility Standards
CMAJ Group

Copyright 2022, CMA Impact Inc. or its licensors. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p)

All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

To receive any of these resources in an accessible format, please contact us at CMAJ Group, 500-1410 Blair Towers Place, Ottawa ON, K1J 9B9; p: 1-888-855-2555; e: cmajgroup@cmaj.ca

Powered by HighWire